{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459588924
| type = mab
| image = 
| alt = 
| mab_type = mab
| source = zu/o
| target = [[MUC1]]
<!-- Clinical data -->
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 868747-45-9
| ATCvet = 
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D10454
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Cantuzumab ravtansine''' (huC242-SPDB-DM4) is an [[antibody-drug conjugate]] designed for the treatment of cancers. The humanized [[monoclonal antibody]] ''cantuzumab'' (huC242) is linked to a [[cytotoxic agent]], [[ravtansine]] (DM4).<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://whqlibdoc.who.int/druginfo/25_2_2011_INN105.pdf | format=PDF}}</ref> It uses a more hindered [[disulfide]] linkage than [[cantuzumab mertansine]].<ref>[https://books.google.co.uk/books?id=WQgaB6VJq_4C&pg=PA131&lpg=PA131&dq=cantuzumab+ravtansine&source=bl&ots=mngfKcpgS5&sig=KtBfUUK49wrOMHCad3al8LBrE1w&hl=en&sa=X&ved=0CDsQ6AEwBWoVChMI_f2pwrjGxwIVSboaCh0xhQef#v=onepage&q=cantuzumab%20ravtansine&f=false Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to ...]</ref>

== See also ==
* [[Cantuzumab mertansine]]
* [[ImmunoGen|ImmunoGen Inc]], developer of DM4 based drugs

== References ==
<references/>

{{monoclonals for tumors}}

[[Category:Immunology]]
[[Category:Monoclonal antibodies]]

{{monoclonal-antibody-stub}}